|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Galaxy Biotech, LLC
| | | Phone: | (408) 400-8020 | Year Established: | 2002 | Employees: | 8 | Main Contact: | Cary Queen, Ph.D., President | | Other Contacts: | K. Jin Kim, Ph.D., CSO James Larrick, M.D., Co-Founder
| | Company Description | Galaxy Biotech has developed novel mAbs against Fibroblast Growth Factor 2 (FGF2) and FGF Receptor 2 (FGFR2). Both the growth factor and receptor play important roles in angiogenesis and the growth of many tumors, especially hepatocellular carcinoma (HCC) for FGF2 and gastric cancer for FGFR2. The mAbs block all biological activities of their targets and strongly inhibit growth of HCC and gastric tumor xenografts respectively. Galaxy is currently seeking a corporate partner to develop the anti-FGF2 antibody.
Galaxy has not sought venture capital funding, instead relying initially on funding from its founders, then on Phase I and Phase II SBIR grants, and now on a combination of SBIR grants and funding from its corporate partners. As a result, the Company has grown slowly, and currently has 8 employees, 5 of them Ph.D.-level scientists and 2 of them at the research assistant level, with a high level of expertise in molecular and cell biology, immunology, and/or animal models. Galaxy leases approximately 3000 sq. ft of laboratory space, which was fully built out and equipped according to the Company’s specifications. | |
|
|
|
|
|